Chime Biologics Forms Strategic Partnership with MedPacto
Chime Biologics, a leading global Contract Development and Manufacturing Organization (CDMO), has embarked on a significant collaboration with MedPacto, a prominent company in South Korea focused on developing innovative cancer therapies. This strategic partnership aims to enhance biologics development and manufacturing processes, facilitating a quicker path to global markets for advanced therapeutics.
Partnership Objectives and Goals
The collaboration will leverage Chime Biologics' expertise in the field of biologics, particularly in streamlining the transition from technical transfer to compliant good manufacturing practices (cGMP) for Investigational New Drug (IND) applications. Both companies are dedicated to advancing their respective missions in the biopharmaceutical field, focusing on the development of multiple preclinical drug candidates.
Statements from Leadership
Dr. Jungwon Woo, who serves as President of MedPacto, expressed enthusiasm for the partnership, stating, "We are highly impressed by Chime Biologics' development and manufacturing expertise, crucial for expanding our reach into major global markets. Their adherence to international standards will significantly boost our ability to advance our assets to the next stage. This collaboration marks a pivotal move forward, and we eagerly anticipate a fruitful long-term partnership."
Dr. Jimmy Wei, President of Chime Biologics, echoed these sentiments, highlighting the importance of this collaboration for both entities. He said, "We are thrilled to collaborate with MedPacto, a respected company with a remarkable portfolio of innovative assets. This partnership represents the beginning of a sustained relationship aimed at fostering pharmaceutical innovation, complementing our overarching growth strategy while reinforcing our commitment to the region's biopharmaceutical landscape. We are looking forward to contributing to the success of MedPacto's innovative pipeline."
Expanding Capabilities in the Industry
As part of its growth strategy, Chime Biologics is enhancing its manufacturing capabilities, expanding to a remarkable 100,000 liters. This expansion solidifies its position as a leading global CDMO. The company is keenly entering the South Korean market and has initiated agreements with several South Korean biotech firms for providing development and manufacturing services, specifically for antibody drugs and biosimilars.
About MedPacto and Its Innovations
MedPacto specializes in biomarker-driven drug discovery, particularly in the realm of innovative cancer therapies. By undertaking comprehensive pre-clinical studies and global clinical trials, MedPacto steadfastly ensures treatment effectiveness. The company is adept at aligning its pipeline with emerging trends in the industry, effectively meeting the rising demand for more effective cancer therapies.
About Chime Biologics
Chime Biologics is a premier global CDMO that has revolutionized the biopharmaceutical sector by introducing the pioneering modular biopharmaceutical plant, KUBio. It empowers partners from cell line development through to commercial manufacturing. With state-of-the-art development initiatives stemming from its Innovation Center, Chime Biologics provides comprehensive Chemistry, Manufacturing, and Controls (CMC) solutions for biopharmaceutical customers across the globe.
Frequently Asked Questions
What is the purpose of the partnership between Chime Biologics and MedPacto?
The partnership aims to enhance drug development and manufacturing processes, facilitating quicker access to global markets for cancer therapies.
Who are the leaders of Chime Biologics and MedPacto?
Dr. Jungwon Woo is the President of MedPacto, while Dr. Jimmy Wei serves as the President of Chime Biologics.
What are the main goals of this collaboration?
The primary goals include streamlining the tech transfer process and advancing multiple preclinical drug candidates through compliant cGMP manufacturing.
What advancements is Chime Biologics making in its manufacturing capacity?
Chime Biologics is expanding its manufacturing capacity to 100,000 liters, solidifying its role as a leader in the global CDMO market.
What is MedPacto's focus in the biopharmaceutical space?
MedPacto specializes in biomarker-driven drug discovery, focusing on innovative therapies for cancer through rigorous pre-clinical studies and global clinical trials.
